{"id":"NCT05069649","sponsor":"Materia Medica Holding","briefTitle":"Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2","officialTitle":"Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Ergoferon as Non-specific COVID-19 Prevention During Vaccination Against SARS-CoV-2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-06","primaryCompletion":"2022-04-14","completion":"2022-04-14","firstPosted":"2021-10-06","resultsPosted":"2024-12-05","lastUpdate":"2024-12-05"},"enrollment":1057,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Immunization Against COVID-19"],"interventions":[{"type":"DRUG","name":"Ergoferon","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ergoferon","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial.\n\nThe objective of this study is to evaluate the efficacy and safety of Ergoferon as a non-specific preventive medicine for COVID-19 in individuals vaccinated against a new coronavirus infection (SARS-CoV-2)","primaryOutcome":{"measure":"The Number of Laboratory-confirmed SARS-CoV-2 Infections.","timeFrame":"3 weeks","effectByArm":[{"arm":"Ergoferon","deltaMin":7,"sd":null},{"arm":"Placebo","deltaMin":22,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0046"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":33,"countries":["Russia"]},"refs":{"pmids":["37167165"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":526},"commonTop":["Increased blood pressure","Headache","Nausea","Viral respiratory tract infection","Migraine"]}}